Cell Therapy News

The FDA granted fast track designation to VOR33, an engineered allogeneic stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse.

The FDA cleared an investigational new drug application for a T-cell receptor therapy designed to treat adults with solid epithelial cancers that express Kita-Kyushu lung cancer antigen 1.

The FDA approved the first chimeric antigen receptor therapy in 2017, authorizing tisagenlecleucel for treatment of children or young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

The FDA cleared an investigational new drug application for GCC19CART, a chimeric antigen receptor T-cell therapy designed to treat patients with relapsed or refractory metastatic colorectal cancer.

Cristina Puig-Saus, PhD, and Daniel S. Shin, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center received a $1 million award from the U.S. Department of Defense for research into novel cell therapies for rare melanomas.

Renier Brentjens, MD, PhD, has been appointed deputy director and chair of the department of medicine of Roswell Park Comprehensive Cancer Center.

For years, hematopoietic stem cell transplantation physicians have viewed a matched unrelated donor as the gold standard when a matched related donor is unavailable.

The FDA cleared an investigational new drug application for a chimeric antigen receptor T-cell therapy designed to treat women with relapsed epithelial ovarian cancer.

The FDA cleared an investigational new drug application for P-BCMA-ALLO1, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma.

National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.